Is Aeolus Pharmaceuticals, Inc. (AOLS) a Buy, Sell, or Hold?
OTC : AOLS
Aeolus Pharmaceuticals, Inc.
$0.0001 USD
$0 (0.0%)
- Volume
- 100K
- Average Volume
- 821
- Market Capitalization
- $15.21K
- P/E Ratio
- 0.00
- Dividend Yield
- 0.00%
- Price Target
- Year High
- $0.00
- Year Low
- $0.00
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.25
Company Overview
OTC
Christopher Stanley
Drug Manufacturers - Specialty & Generic
Healthcare
AOLS
4
US
USD
Liquidity Metrics
0.00
4.25
4.25
3.25
0.00
Sales & Valuation
$2.08M
0.01
0.00
0.00
-0.02
Profitability
-$0.04
-$3.56M
-171.39%
-171.39%
-302.81%
-85.39%
P/E Metrics
0.00
0.00
0.00
Analyst Price Target & Rating
0/5
0 Analysts
%
Financial Health Scores
-373.54
1/9
$175K
$794K
$587K
-$8.19M
Key Metrics (TTM)
-$3.14M
-1.51
0.96
4.25
-302.81%
-102.44%
-23932.52%
-20441.84%
9 days
Company Executives
| Name | Title |
|---|---|
| Christopher Stanley | Vice President of Operations |
Poll Results
No votes yet today — be the first to share your view!
About Aeolus Pharmaceuticals, Inc. (OTC:AOLS) Stock
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical firm specializing in the development of innovative therapeutic compounds. Operating within the United States, the company's research pipeline addresses a diverse range of critical medical challenges, including biodefense, fibrotic conditions, oncology, infectious diseases, and central nervous system disorders. A core focus involves a distinct class of catalytic antioxidant compounds, which are being advanced as essential medical countermeasures against threats from nuclear, radiological, and chemical weapons, in addition to therapies for respiratory, neurological, and oncological ailments. Their flagship product candidate, AEOL 10150, has successfully navigated two Phase I clinical trials. This compound is being developed to combat the pu ... lmonary complications associated with acute radiation syndrome, and also serves as a crucial protective agent against exposure to chemical vesicants and nerve agents. Further expanding its pipeline, Aeolus is also pursuing AEOL 11114B, AEOL 11203, and AEOL 11207 for the treatment of Parkinson's disease, alongside AEOL 20415, designed to address various infectious diseases. Established in 1994, Aeolus Pharmaceuticals is headquartered in Mission Viejo, California.
Frequently Asked Questions
-
What is the current Aeolus Pharmaceuticals, Inc. (AOLS) stock price?
-
Aeolus Pharmaceuticals, Inc.(OTC:AOLS) stock price is $0.0001 in the last trading session. During the trading session, AOLS stock reached the peak price of $0.0001 while $0.0001 was the lowest point it dropped to. The percentage change in AOLS stock occurred in the recent session was 0.0% while the dollar amount for the price change in AOLS stock was $0.
-
AOLS's industry and sector of operation?
-
The OTC listed AOLS is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector.
-
Who are the executives of AOLS?
-
Christopher Stanley | Vice President of Operations
|
|
|
| -
How many employees does AOLS have?
-
Number of AOLS employees currently stands at 4. AOLS operates from 27800 Medical Center Rd, Mission Viejo, CA 92691, US.
-
Link for AOLS official website?
-
Official Website of AOLS is: https://www.aeoluspharma.com
-
How do I contact AOLS?
-
AOLS could be contacted at phone #949-481-9825 and can also be accessed through its website. AOLS operates from 27800 Medical Center Rd, Mission Viejo, CA 92691, US.
-
How many shares of AOLS are traded daily?
-
The average number of AOLS shares traded daily for last 3 months was 821.
-
What is the market cap of AOLS currently?
-
The market value of AOLS currently stands at $15.21K with its latest stock price at $0.0001